Pure Global
NCT06418061

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

A Phase 1, Multicenter, Open-label Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
IBI3005
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Location
Nedlands, Australia
Timeline & enrollment
Phase
Phase 1
Start date
Jun 30, 2024
End date
Jun 30, 2027
Enrollment
198 participants
Primary outcome

Number of subjects with adverse events,Number of subjects with clinically significant changes in physical examination results,Number of subjects with clinically significant changes in vital signs,Dose limiting toxicities (DLTs)

Summary

The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to
 determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of
 IBI3005.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06418061
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06418061 through Pure Global AI's free database. This Phase 1 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 198 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.